Show simple item record

dc.contributor.authorKhan, Shahzadgai
dc.contributor.authorAlbayaty, Muna
dc.contributor.authorBush, James
dc.contributor.authorCheriyan, Joseph
dc.contributor.authorCromie, Anthea
dc.contributor.authorKoch, Annelize
dc.contributor.authorHammond, Michael
dc.contributor.authorMair, Stuart
dc.contributor.authorLorch, Ulrike
dc.contributor.authorStringer, Steffan
dc.contributor.authorTaubel, Jorg
dc.contributor.authorHardman, Timothy C.
dc.date.accessioned2020-12-22T19:01:12Z
dc.date.available2020-12-22T19:01:12Z
dc.date.issued2020-11-19
dc.date.submitted2020-07-06
dc.identifier.other580560
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/315478
dc.description.abstractThe Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation, and future challenges facing early phase drug development as we move into the second decade of the 21th century. The meeting opened with discussion around the technical revolution in pharmaceutical medicine over the 4 decades since the AHPPI was founded and how transformative technologies have accompanied the introduction of processes such as physiologically based pharmacokinetic modeling. During the meeting examples were presented of how in terms of the development of new therapies, the classic phases of clinical drug development are becoming a thing of the past and the lines between the phases have begun to blur, particularly in the field of oncology. The contribution that monoclonal antibodies have made to medicine and the next chapter in their design and use was also discussed. A representative of the UK’s Medicine and Healthcare Products Regulatory Agency discussed the increasing numbers of requests to approve complex innovative design trials, how novel trial designs are impacting on the traditional linear “phase” approach to drug development and the common pitfalls associated with them. Guidance was provided from a regulator’s viewpoint on what was meant by the term “novel design” and how to submit successful trial applications for such complex trials. In an Oxford-style debate, the audience discussed the motion that “there is no longer a need to include placebo subjects in early clinical trials.” The keynote speaker focused on delivering change in complex environments such as the field of drug development. The afternoon session included presentations on the challenges associated with drug product design, the complexities within non-oral dosage forms and proposed new methods of formulations for drug delivery. Presentations were also given on advances in mechanistic and computational pharmacokinetic modeling and how they have proved to be valuable tools to rationalize and facilitate the process of drug development.
dc.languageen
dc.publisherFrontiers Media S.A.
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectPharmacology
dc.subjectearly phase clinical development
dc.subjectmeeting report
dc.subjectAssociation for Human Pharmacology in the Pharmaceutical Industry
dc.subjectinnovation
dc.titleThe Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges
dc.typeArticle
dc.date.updated2020-12-22T19:01:11Z
prism.publicationNameFrontiers in Pharmacology
prism.volume11
dc.identifier.doi10.17863/CAM.62585
dcterms.dateAccepted2020-10-08
rioxxterms.versionofrecord10.3389/fphar.2020.580560
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.identifier.eissn1663-9812


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)